Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

COVID-19 2 Skin Neoplasms 1 Respiratory Sounds 1 Neoplasms 1 Lymphoma, Follicular 1 Hematologic Neoplasms 1 Crohn Disease 1 Asthma 1

Interventions

Cyclophosphamide 72 fludarabine 65 Tacrolimus 43 fludarabine phosphate 40 Whole-Body Irradiation 37 Mycophenolic Acid 35 Busulfan 32 Melphalan 28 Antilymphocyte Serum 23 thymoglobulin 22 Thiotepa 20 Methotrexate 20 Standard of Care 19 Stem Cell Transplantation 17 Practice Guidelines as Topic 17 Granulocyte Colony-Stimulating Factor 17 Rituximab 15 Surveys and Questionnaires 12 Sirolimus 12 Filgrastim 12 Interviews as Topic 11 Cyclosporine 11 Blood Specimen Collection 11 Peripheral Blood Stem Cell Transplantation 10 Exercise 10 venetoclax 9 Mesna 9 Cytarabine 9 Bortezomib 9 Hematopoietic Stem Cell Transplantation 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Hematologic Neoplasms × Azithromycin × Clear all

NCT04392128 2020-09-04

HYACINTHE

Institut de cancérologie Strasbourg Europe

Phase 2 Withdrawn

Other hematologic neoplasm

COVID-19, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡